#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Sandra Spalek"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/cf4d8bb88754f036b943b4d94ad96e103dcb7149/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/73688d6dc24e309fca59a1340dc9ee971e9f3baa/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/a5b84013a08880975ca84f40999e4404b14a97e2/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

# Add statements below this comment

SET Citation = {"PubMed","28528849"}

# Pro-aggregant tau: TauRDΔK280 : p(HBP:"Tau oligomers",var("p.Lys280del"))
# in this paper the mutant refers to Tau oligomers
# general references and not results refer to p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del"))

SET Evidence = "TauRDΔK comprises the structural elements required for the
pathologic assembly of tau filaments, and it causes reversible
memory deficits and synapse loss in regulatable transgenic mice [11,25]."
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) -| bp(GO:memory)
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) -| a(GO:synapse)
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) -> a(HBP:"Tau fibrils")

SET Evidence = "Analysis of sarkosyl extracts of brain homogenates of mice expressing the pro-aggregant
repeat domain TauRDΔK revealed that oligomers are present, partly in a disulfide–cross-linked form (Supplementary Fig. 1)."
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) -> a(HBP:"Tau oligomers")

# thioflavin S (ThS) or 8-anilino-1-naphthalenesulfonate (ANS)

SET Evidence = "During early stages of assembly, there is some increase in ThS intensity, combined with a pronounced increase in
ANSfluorescence (Fig. 2Aand B), which is due to oligomers, indicating a change in conformation without increase in beta-structure"
# monomeric TauRDΔK assembly to oligomers
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) -> p(HBP:"Tau oligomers",var("p.Lys280del"))

SET Evidence = "During the transition from oligomers to polymers, the ANS fluorescence remains roughly constant, whereas
ThS fluorescence increases strongly (Fig. 2B)"
# high ThS signal: fibrils
p(HBP:"Tau oligomers",var("p.Lys280del")) -> p(HBP:"Tau fibrils",var("p.Lys280del"))

SET Evidence = "To address this question, we first applied the oligomers directly after the purification of the protein eluting from the Butyl FF 16/
10 column (without buffer exchange; 1, 5, and 10 mM) to SHSY5Y cells and observed a variety of toxic effects, including
pronounced reduction in the cell viability (by MTT assay, Fig. 3A), increase in apoptotic cells (by Hoechst staining,
Supplementary Fig. 4A), loss of mitochondrial membrane potential (by JC1 assay, Supplementary Fig. 4B), caspase 3/7 activation
(Supplementary Fig. 4C-D), and cytochrome-c release (Supplementary Fig. 4), within 5 hours of incubation."
#oligomers: p(HBP:"Tau oligomers",var("p.Lys280del"))
SET CellLine = "SK-N-SH"
p(HBP:"Tau oligomers",var("p.Lys280del")) -> bp(GO:"cell death")
p(HBP:"Tau oligomers",var("p.Lys280del")) -> bp(GO:"apoptotic process")
p(HBP:"Tau oligomers",var("p.Lys280del")) -> bp(GO:"negative regulation of mitochondrial membrane potential")
p(HBP:"Tau oligomers",var("p.Lys280del")) -> act(p(HGNC:CASP3))
p(HBP:"Tau oligomers",var("p.Lys280del")) -> act(p(HGNC:CASP7))
p(HBP:"Tau oligomers",var("p.Lys280del")) -> sec(p(HGNC:CYCS))
UNSET CellLine

SET Evidence = "There was no significant change in the LDH release in oligomer-treated cells compared with controls
indicating that TauRDΔK oligomers do not compromise the membrane integrity (Supplementary Fig. 5G-H)."
SET CellLine = "SK-N-SH"
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc a(GO:membrane)
UNSET CellLine

SET Evidence = "As shown earlier, TauRDΔK-expressing mice display loss of
neurons in the CA3 and other regions of the hippocampus [11,24]."
SET MeSHAnatomy = "CA3 Region, Hippocampal"
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) -| a(MESH:Neurons)
UNSET MeSHAnatomy

SET Evidence = "We reasoned that microglia and other cell types in the hippocampus might act as mediators for the
cytotoxicity caused by TauRDΔK oligomers, which could explain why cytotoxicity was not observed in the cell
culture systems."
a(MESH:Microglia) reg act(p(HBP:"Tau oligomers",var("p.Lys280del")))

SET Evidence = "Consistent with this, NeuN staining of the slices fixed after 48 hours of treatment with TauRDΔK oligomers
revealed no reduction in the neuronal number in all regions of the hippocampus (CA1, CA3, and DG) (Fig. 3C and
D, Supplementary Fig. 7), confirming that TauRDΔK oligomers do not cause cell death in the OHSC model as well."
# OHSC model: ex vivo method to examine mechanisms of neuronal injury
SET MeSHAnatomy = {"CA3 Region, Hippocampal","CA1 Region, Hippocampal","CA2 Region, Hippocampal"}
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc bp(GO:"cell death")
UNSET MeSHAnatomy

# aggregates of recombinant human full-length tau protein (ht40 wt, 2N4R)

SET Evidence = "In our hands, these aggregated tau species formed in different conditions did not show any significant release of
LDH when applied on the differentiated SH-SY5Y cells (Supplementary Fig. 8A), and they did not show a significant
reduction in cell viability by the MTTassay (Supplementary Fig. 8B)."
SET CellLine = "SK-N-SH"
a(HBP:"Tau aggregates") cnc bp(GO:"cell death")
a(HBP:"Tau aggregates") cnc a(GO:membrane)
UNSET CellLine

SET Evidence = "Recently, extracellular tau oligomers were shown to impair long term potentiation (LTP) and memory [40]."
SET MeSHAnatomy = "Extracellular Space"
a(HBP:"Tau oligomers") -| bp(GO:"long-term synaptic potentiation")
a(HBP:"Tau oligomers") -| bp(GO:memory)
UNSET MeSHAnatomy

SET Evidence = "In this case, there was a dramatic loss (up to 50%) of spines in TauRDΔK oligomer-treated cells
compared with monomer-treated cells (Fig. 4A and B, bar 3)."
p(HBP:"Tau oligomers",var("p.Lys280del")) -| a(MESH:"Dendritic Spines")

SET Evidence = "The fibril-treated cells (cross-linked with GA or not) did not reduce the spine density significantly (Fig 4C, bars
8 and 9)."
a(HBP:"Tau fibrils") -| a(MESH:"Dendritic Spines")

SET Evidence = "For comparison, in the case of Ab oligomers, only higher concentrations
(w1 mM) cause an appreciable spine reduction of w30% (Fig. 4C, bar 3) (Zempel et al., 2010 [30])."
a(HBP:"AβOs") -| a(MESH:"Dendritic Spines")

SET Evidence = "PSD-95, a marker of postsynaptic spines, decreased
up to 50% in the TauRDΔK oligomer-treated cells, compared with buffer- and monomer-treated cells"
SET MeSHAnatomy = "Dendritic Spines"
p(HBP:"Tau oligomers",var("p.Lys280del")) -| a(GO:postsynapse)
UNSET MeSHAnatomy

SET Evidence = "Similarly, the GluR1 subunits of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptors (characteristic of mature spines and necessary for LTP and calcium signaling)
decreased in the oligomer-treated samples up to 60%."
p(HBP:"Tau oligomers",var("p.Lys280del")) -| p(HGNC:GRIA1)

SET Evidence = "Drebrin, a neuronal actin-binding protein involved in spinogenesis
and synaptogenesis, was decreased by up to 60% consistent with the reduced number of spines (Fig. 4D,
bars 3, 6, and 9)."
p(HBP:"Tau oligomers",var("p.Lys280del")) -| p(HGNC:DBN1)
p(HGNC:DBN1) -> bp(GO:"synapse assembly")
p(HBP:"Tau oligomers",var("p.Lys280del")) -| a(MESH:"Dendritic Spines")

SET Evidence = "We also looked at the presynaptic protein synaptophysin, which was not significantly altered in
TauRDΔK oligomer-treated cells compared with buffer- or monomer-treated cells (Fig 4D, bar 12). However, at higher
concentration, synaptophysin tends to be reduced."
p(HBP:"Tau oligomers",var("p.Lys280del")) -| p(HGNC:SYP)

SET Evidence = "We observed an oligomer-dependent increase in the ROS production
in the mature rat primary hippocampal neurons in all cellular compartments (Fig. 5A)."
SET MeSHAnatomy = {"Hippocampus","Neurons"}
p(HBP:"Tau oligomers",var("p.Lys280del")) -> a(CHEBI:"reactive oxygen species")
UNSET MeSHAnatomy

SET Evidence = "By contrast, monomers of TauRDΔK even at 10 mM concentration
did not cause any significant ROS increase (Fig. 5B)."
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) cnc a(CHEBI:"reactive oxygen species")

SET Evidence = "We indeed found that there is an overexpression (w15%) of Nox1 protein (a component of NADPH oxidase
complex) by Western blot, suggesting the role of NADPH oxidase complex as a potential source of ROS"
p(HBP:"Tau oligomers",var("p.Lys280del")) -> p(HGNC:NOX1)
p(HBP:"Tau oligomers",var("p.Lys280del")) -> act(complex(GO:"NADPH oxidase complex"))
act(complex(GO:"NADPH oxidase complex")) -> a(CHEBI:"reactive oxygen species")

SET Evidence = "However, we did not find significant changes in the expression level
of Nox2 protein (another component of NADPH oxidase complex) (Fig. 5C)."
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc p(HGNC:CYBB)

SET Evidence = "These findings suggest that the ROS production induced by extracellular TauRDΔK oligomers might
cause the activation of NADPH oxidase complex"
p(HBP:"Tau oligomers",var("p.Lys280del")) -> act(complex(GO:"NADPH oxidase complex"))
act(complex(GO:"NADPH oxidase complex")) -> a(CHEBI:"reactive oxygen species")

SET Evidence = "The ratio of 340 to 380 nm in TauRDΔK oligomer-treated cells
showed a steady concentration-dependent increase in the intracellular calcium with a maximum reached at 20 minutes
of incubation with oligomers (10 mM) occurring in all cell compartments (Fig. 5D; arrows)."
SET MeSHAnatomy = {"Hippocampus","Neurons"}
p(HBP:"Tau oligomers",var("p.Lys280del")) -> bp(GO:"cellular calcium ion homeostasis")
UNSET MeSHAnatomy

SET Evidence = "By contrast, there was no significant increase in the calcium level in cells treated with
TauRDΔK monomers even at higher concentration (10 mM) (Fig. 5E and F, green curves)."
p(HBP:"Tau isoform F (441 aa)",var("p.Lys280del")) cnc bp(GO:"cellular calcium ion homeostasis")

SET Evidence = "We did not observe any increase in the phosphorylation of the tau
repeat domain (as seen by the antibody 12E8) after treating the neurons with TauRDΔK oligomers."
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc p(HGNC:MAPT,pmod(Ph,Ser,262))

SET Evidence = "We also checked the phosphorylation of tau at other sites (e.g., using the antibody AT8, reacting only with the endogenous
tau) and did not observe an increase in the phosphorylation."
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc p(HGNC:MAPT,pmod(Ph,Ser,202))
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc p(HGNC:MAPT,pmod(Ph,Thr,205))

SET Evidence = "Endogenous tau protein retained its normal axonal localization and did not missort into the
cell body and dendrites (Fig. 6A8), although there was a reduction in the spine density (Fig. 6B6) in the TauRDΔK
oligomer-treated neurons."
SET MeSHAnatomy = "Neurons"
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc tloc(p(HGNC:MAPT),fromLoc(GO:axon),toLoc(GO:"cell body"))
p(HBP:"Tau oligomers",var("p.Lys280del")) cnc tloc(p(HGNC:MAPT),fromLoc(GO:axon),toLoc(MESH:"Dendritic Spines"))
p(HBP:"Tau oligomers",var("p.Lys280del")) -| a(MESH:"Dendritic Spines")
UNSET MeSHAnatomy

SET Evidence = "The results revealed that both TauRDΔK and TauFLΔK oligomers reduce the density
of spines up to 50% compared with the buffer-treated cells."
# TauFLDK: full-length TauFLΔK
p(HBP:"Tau oligomers",var("p.Lys280del")) -| a(MESH:"Dendritic Spines")

SET Evidence = "Tau oligomers from TauRDΔK and TauFLΔK mice reduced the density of the synapses by
w50%, whereas tau from wild-type mice had no effect on the density (Fig. 7G)."
p(HBP:"Tau oligomers",var("p.Lys280del")) -| a(GO:synapse)
p(HGNC:MAPT) cnc a(GO:synapse)
